[go: up one dir, main page]

WO2024182807A3 - Phenylalkylamine prodrugs - Google Patents

Phenylalkylamine prodrugs Download PDF

Info

Publication number
WO2024182807A3
WO2024182807A3 PCT/US2024/018413 US2024018413W WO2024182807A3 WO 2024182807 A3 WO2024182807 A3 WO 2024182807A3 US 2024018413 W US2024018413 W US 2024018413W WO 2024182807 A3 WO2024182807 A3 WO 2024182807A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
phenylalkylamine
psychedelic
methods
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/018413
Other languages
French (fr)
Other versions
WO2024182807A2 (en
Inventor
Nicholas COZZI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexander Shulgin Research Institute Inc
Original Assignee
Alexander Shulgin Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexander Shulgin Research Institute Inc filed Critical Alexander Shulgin Research Institute Inc
Priority to CN202480029191.6A priority Critical patent/CN121127458A/en
Priority to IL323075A priority patent/IL323075A/en
Publication of WO2024182807A2 publication Critical patent/WO2024182807A2/en
Publication of WO2024182807A3 publication Critical patent/WO2024182807A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Provided herein are prodrugs of phenylalkylamines (e.g., psychedelic phenethylamines) that incorporate a vitamin B6-based promoiety (e.g., pyridoxal). Also provided are methods of making such compounds, pharmaceutical compositions thereof, and methods of their use, such as in the treatment of mental health disorders, neurodegenerative conditions, pain disorders, and inflammation, including as part of psychedelic-assisted therapy. (I)
PCT/US2024/018413 2023-03-02 2024-03-04 Phenylalkylamine prodrugs Pending WO2024182807A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202480029191.6A CN121127458A (en) 2023-03-02 2024-03-04 Phenylalkylamine prodrugs
IL323075A IL323075A (en) 2023-03-02 2024-03-04 Phenylalkylamine prodrugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363449511P 2023-03-02 2023-03-02
US63/449,511 2023-03-02
US202363468956P 2023-05-25 2023-05-25
US63/468,956 2023-05-25

Publications (2)

Publication Number Publication Date
WO2024182807A2 WO2024182807A2 (en) 2024-09-06
WO2024182807A3 true WO2024182807A3 (en) 2024-11-14

Family

ID=92590513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/018413 Pending WO2024182807A2 (en) 2023-03-02 2024-03-04 Phenylalkylamine prodrugs

Country Status (3)

Country Link
CN (1) CN121127458A (en)
IL (1) IL323075A (en)
WO (1) WO2024182807A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180186797A1 (en) * 2015-04-27 2018-07-05 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180186797A1 (en) * 2015-04-27 2018-07-05 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM SUBSTANCE 31 December 2020 (2020-12-31), ANONYMOUS: "[(4Z)-4-[[(Z)-2-(4hydroxyphenyl)ethylideneamino]me thylidene]-6-methyl-5-oxidanyl-1Hpyridin-3-yl]methyl dihydrogen phosphate ", XP093239050, Database accession no. 439504503 *
HEYL DOROTHEA, LUZ EILEEN, HARRIS STANTON A, FOLKERS KARL: "Chemistry of Vitamin B6. VII Pyridoxylidene- and Pyridoxylamines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 70, no. 11, 1 November 1948 (1948-11-01), pages 3669 - 3671, XP093239044, DOI: 10.1021/ja01191a038 *
HEYL DOROTHEA, LUZ EILEEN, HARRIS STANTON A, FOLKERS KARL: "Chemistry of Vitamin B6. VIII. Additional Pyridoxylideneamines and Pyridoxylamines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 74, no. 2, 1 January 1952 (1952-01-01), pages 414 - 416, XP093239042, DOI: 10.1021/ja01122a038 *
NAKAZAWA HIDETSUGU, KUMAGAI HIDEHIKO, YAMADA HIDEAKI: "Decarboxylation Reaction of a-Methyl Amino Acid Catalyzed by Aromatic I-Amino Acid Decarboxylase from Micrococcus percitreus", AGRICULTURAL AND BIOLOGICAL CHEMISTRY, AGRICULTURAL CHEMICAL SOCIETY OF JAPAN, JP, vol. 49, no. 1, 1 January 1985 (1985-01-01), JP , pages 159 - 165, XP093239047, ISSN: 0002-1369, DOI: 10.1080/00021369.1985.10866677 *
WOJTAS, A ET AL.: "Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats", NEUROTOXICITY RESEARCH, vol. 39, no. 2, 18 December 2020 (2020-12-18), pages 305 - 326, XP037407946, DOI: 10.1007/s12640-020-00297-8 *

Also Published As

Publication number Publication date
IL323075A (en) 2025-10-01
CN121127458A (en) 2025-12-12
WO2024182807A2 (en) 2024-09-06

Similar Documents

Publication Publication Date Title
AU2023251426B2 (en) Combinations of cannabinoids and N-acylethanolamines
Hedges et al. An open trial of nefazodone in adult patients with generalized anxiety disorder
NO20035473D0 (en) Orally administered dosage forms of GABA analog prodrugs which have reduced toxicity
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
MX344787B (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders.
DE602006014694D1 (en) ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAN ACID AND APPLICATION
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2005035485A3 (en) Analgesic compounds, their synthesis and pharmaceutical compositions containing them
BRPI0408863A (en) compound, pharmaceutical composition, method for treating diseases, and use of a compound.
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
WO2024182807A3 (en) Phenylalkylamine prodrugs
MX2025002176A (en) Tyk2 inhibitors and uses thereof
BR0316451A (en) Synergistically combination comprising roflumilast and formoterol
BRPI0409170A (en) combinations comprising antiepileptic drugs for the treatment of neurological disorders
FR2887150B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE INGREDIENT
KR20070008451A (en) How to treat osteoarthritis
ITMI20031941A1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS FOR DERMATITIS TREATMENT
WO2023009817A3 (en) Phosphate prodrugs of cannabinoids
DE60321954D1 (en) SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND (R, R) -FORMOTEROL
DK1643997T3 (en) Flupirtine preparation for the treatment of neurodegenerative disorders of the visual apparatus and diabetes mellitus
WO2006055381A3 (en) Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
CN108366977A (en) Curcumin and resveratrol for chronic inflammation
IL316787A (en) Azetidine compounds, pharmaceutical compositions thereof, preparation methods and their uses in the treatment of cns disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 323075

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024764717

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24764717

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024764717

Country of ref document: EP

Effective date: 20251002

ENP Entry into the national phase

Ref document number: 2024764717

Country of ref document: EP

Effective date: 20251002

ENP Entry into the national phase

Ref document number: 2024764717

Country of ref document: EP

Effective date: 20251002